Literature DB >> 33611692

Glycogen synthase kinase 3 beta inhibitor SB216763 improves Kir2.1 expression after myocardia infraction in rats.

Cheng Chang1, Shu-Hui Wang1, Li-Na Xu1, Xue-Ling Su1, Yi-Fan Zeng1, Peng Wang2, Li-Rong Zhang1, Sheng-Na Han3.   

Abstract

BACKGROUND: Abnormal ion channel currents caused by myocardial electrical remodeling is one of the main causes of malignant arrhythmias. Glycogen synthase kinase 3β (GSK-3β) is the main therapeutic target following ischemia as it regulates nerve cell channels. However, few studies have investigated its role in myocardial electrical remodeling. The present study aimed to investigate the role of GSK-3β in a rat myocardial infarction (MI)-induced electrical remodeling and potential effects on cardiac ionic channels including KCNJ2/Kir2.1/IK1.
METHODS: Ligation of the left anterior descending artery in rats was performed to establish a MI model. The rats were randomly divided into three groups, the sham, MI, and MI + SB group. The animals in the latter group were administered SB216763 (GSK-3β inhibitor) at a dose of 0.6 mg·kg-1·day-1. The ventricular function was assessed by echocardiography, electrocardiography, and histological analysis 7 days post-surgery. Serum was collected to measure lactate dehydrogenase and cardiac troponin I levels, and the mRNA and protein levels of the KCNJ2/Kir2.1/IK1 channel in the heart tissues were assessed. H9c2 cells were cultured to examine the effects of SB216763 on the protein expression of Kir2.1 channel under hypoxic conditions.
RESULTS: The results revealed that SB216763 ameliorated acute cardiac injury and improved myocardial dysfunction. Moreover, SB216763 increased the mRNA and protein expression of Kir2.1 during MI. Furthermore, SB216763 treatment abrogated the decreased expression of Kir2.1 in H9c2 cells under hypoxic conditions.
CONCLUSIONS: GSK-3β inhibition upregulates Kir2.1 expression in a rat model of MI.
© 2021. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Electrical remodeling; Glycogen synthase kinase 3; Inwardly rectifying potassium channel; Myocardial infarction

Mesh:

Substances:

Year:  2021        PMID: 33611692     DOI: 10.1007/s10840-021-00963-7

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


  32 in total

Review 1.  Pharmacological exploration of the resting membrane potential reserve: Impact on atrial fibrillation.

Authors:  Marcel A G van der Heyden; Thomas Jespersen
Journal:  Eur J Pharmacol       Date:  2015-11-18       Impact factor: 4.432

Review 2.  Glycogen synthase kinases: Moonlighting proteins with theranostic potential in cancer.

Authors:  Siddavaram Nagini; Josephraj Sophia; Rajakishore Mishra
Journal:  Semin Cancer Biol       Date:  2018-01-05       Impact factor: 15.707

3.  Overexpression of KCNJ2 in induced pluripotent stem cell-derived cardiomyocytes for the assessment of QT-prolonging drugs.

Authors:  Min Li; Yasunari Kanda; Takashi Ashihara; Tetsuo Sasano; Yuji Nakai; Masami Kodama; Erina Hayashi; Yuko Sekino; Tetsushi Furukawa; Junko Kurokawa
Journal:  J Pharmacol Sci       Date:  2017-05-27       Impact factor: 3.337

Review 4.  Acute Myocardial Infarction.

Authors:  Jeffrey L Anderson; David A Morrow
Journal:  N Engl J Med       Date:  2017-05-25       Impact factor: 91.245

Review 5.  Glycogen synthase kinase-3 and its inhibitors: Potential target for various therapeutic conditions.

Authors:  A Prasanth Saraswati; S M Ali Hussaini; Namballa Hari Krishna; Bathini Nagendra Babu; Ahmed Kamal
Journal:  Eur J Med Chem       Date:  2017-12-09       Impact factor: 6.514

6.  Valsartan ameliorates KIR2.1 in rats with myocardial infarction via the NF-κB-miR-16 pathway.

Authors:  Xinran Li; Hesheng Hu; Ye Wang; Mei Xue; Xiaolu Li; Wenjuan Cheng; Yongli Xuan; Jie Yin; Na Yang; Suhua Yan
Journal:  Gene       Date:  2015-12-01       Impact factor: 3.688

Review 7.  Epidemiology of coronary heart disease and acute coronary syndrome.

Authors:  Fabian Sanchis-Gomar; Carme Perez-Quilis; Roman Leischik; Alejandro Lucia
Journal:  Ann Transl Med       Date:  2016-07

8.  Control of neuronal ion channel function by glycogen synthase kinase-3: new prospective for an old kinase.

Authors:  Norelle C Wildburger; Fernanda Laezza
Journal:  Front Mol Neurosci       Date:  2012-07-16       Impact factor: 5.639

9.  Overexpression of Cx43 in cells of the myocardial scar: Correction of post-infarct arrhythmias through heterotypic cell-cell coupling.

Authors:  Wilhelm Roell; Alexandra M Klein; Martin Breitbach; Torsten S Becker; Ashish Parikh; Jane Lee; Katrin Zimmermann; Shaun Reining; Beth Gabris; Annika Ottersbach; Robert Doran; Britta Engelbrecht; Miriam Schiffer; Kenichi Kimura; Patricia Freitag; Esther Carls; Caroline Geisen; Georg D Duerr; Philipp Sasse; Armin Welz; Alexander Pfeifer; Guy Salama; Michael Kotlikoff; Bernd K Fleischmann
Journal:  Sci Rep       Date:  2018-05-08       Impact factor: 4.379

10.  GABAB R/GSK-3β/NF-κB signaling pathway regulates the proliferation of colorectal cancer cells.

Authors:  Qing Shu; Jun Liu; Xiupeng Liu; Sufang Zhao; Hualin Li; Yonggang Tan; Jianming Xu
Journal:  Cancer Med       Date:  2016-04-05       Impact factor: 4.452

View more
  2 in total

1.  The caspase-1 inhibitor VX765 upregulates connexin 43 expression and improves cell-cell communication after myocardial infarction via suppressing the IL-1β/p38 MAPK pathway.

Authors:  Xue-Ling Su; Shu-Hui Wang; Sumra Komal; Liu-Gen Cui; Rui-Cong Ni; Li-Rong Zhang; Sheng-Na Han
Journal:  Acta Pharmacol Sin       Date:  2022-02-07       Impact factor: 7.169

2.  Targeting Glycogen Synthase Kinase 3 Beta Regulates CD47 Expression After Myocardial Infarction in Rats via the NF-κB Signaling Pathway.

Authors:  Li-Na Xu; Shu-Hui Wang; Xue-Ling Su; Sumra Komal; Hong-Kun Fan; Li Xia; Li-Rong Zhang; Sheng-Na Han
Journal:  Front Pharmacol       Date:  2021-07-19       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.